Noncoding elements within MYCN mRNA are autonomous drivers of oncogenesis in neuroblastoma
Preprint
Abstract
Neuroblastoma (NB) is a highly metastatic pediatric cancer arising from the neural crest lineage. Genetic amplification of the MYCN proto-oncogene is a defining feature of NB, present in about 20% of all cases. The let-7 tumor suppressor microRNA targets the 3’ UTR of MYCN mRNA. We previously demonstrated that the 3’ UTR of MYCN mRNA acquires the ability to sequester let-7 in MYCN -amplified ( MA ) disease, thus inhibiting its function. This work established that a noncoding element within an oncogenic mRNA can contribute independently to disease pathology and genetic patterning. To further investigate the roles of noncoding RNA elements within the MYCN mRNA, we engineered cells expressing either MYCN-ORF (MYCN open reading frame only), MYCN-GL (full-length MYCN mRNA from the intact genetic locus), and Null-GL (full-length MYCN mRNA variant where EGFP replaces MYCN protein). We observe that all constructs enhance growth compared to controls in vitro and in vivo. MYCN-GL -expressing cells displayed the most robust growth in vitro despite containing multiple regulatory RNA elements. Remarkably, the Null-GL construct induces cells to grow as fast or faster than MYCN-ORF -expressing cells. Animal studies further confirmed these observations, where the Null-GL -driven tumors had the highest incidence and lowest latency, followed by MYCN-GL and then MYCN-ORF . Further, through NGS analysis, let-7, miR-101 , and miR-34a targets are enriched in both MYCN-GL and Null-GL expressing cells. Thus, the 3’UTR of MYCN , which is also targeted by these microRNAs, may interact with them in MYCN-GL and Null-GL cells to deliver a protective effect for the mRNA targets of these microRNAs. We also observed more dynamic differential gene expression in the -GL constructs than in ORF and GFP-expressing cells. In addition, MYCN-GL and Null-GL expressing cells are similarly enriched in gene ontology pathways for cancer, RNA metabolism, and microRNA processing pathways as compared to ORF and GFP . Whole genome sequencing also revealed more similarities in copy number variation in MYCN-GL and Null-GL than in ORF and GFP , suggesting that these constructs may provide selective pressure to favor specific CNV patterns. These observations show that full-length MYCN mRNA containing noncoding regulatory elements are more robust drivers of cell growth and oncogenicity than MYCN protein alone and provide insights into the mechanisms of oncogenic contribution. These results open an exciting door for our understanding of NB pathology and genetic patterning and have broad implications for other oncogene-driven cancers.Keywords
This publication has 28 references indexed in Scilit:
- The Untranslated Regions of mRNAs in CancerTrends in Cancer, 2019
- Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology GroupCancer, 2017
- Introns and gene expression: Cellular constraints, transcriptional regulation, and evolutionary consequencesBioEssays, 2014
- A Cell-Based High-Throughput Screen Addressing 3′UTR-Dependent Regulation of the MYCN GeneMolecular Biotechnology, 2014
- The let-7 family of microRNAsTrends in Cell Biology, 2008
- let-7 microRNAs in development, stem cells and cancerTrends in Molecular Medicine, 2008
- MYCN regulates oncogenic MicroRNAs in neuroblastomaInternational Journal of Cancer, 2007
- Allelic deletion at chromosome bands 11q14-23 is common in neuroblastomaMedical and Pediatric Oncology, 2001
- Transposition and amplification of oncogene-related sequences in human neuroblastomasCell, 1983
- Transfection by exogenous and endogenous murine retrovirus DNAsCell, 1979